Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shana Medeiros"'
Autor:
Rolf Freter, Elizabeth McMahon, Anthony V. D'Amico, Molly Sullivan, Parvesh Kumar, Jeffrey Y.C. Wong, Glenn J. Bubley, Shana Medeiros, W. Jeffrey Baker, Juan Carlos Vera, David Joseph, Philip W. Kantoff, Wanling Xie, Marian Loffredo, James W. Denham, Richard Hellwig, Andrew A. Renshaw
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(26)
PURPOSEAlthough docetaxel is not recommended when managing men with unfavorable-risk prostate cancer (PC) given negative or inconclusive results from previous randomized trials, unstudied benefits may exist.METHODSBetween September 21, 2005, and Janu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b455348068e62403ae18b9bd22e189
https://pubmed.ncbi.nlm.nih.gov/34534000
https://pubmed.ncbi.nlm.nih.gov/34534000
Autor:
Anthony Victor D'Amico, Wanling Xie, Elizabeth McMahon, Marian Loffredo, Shana Medeiros, David John Joseph, James William Denham, David S Lamb, Parvesh Kumar, Glenn Bubley, Molly A. Sullivan, Richard Hellwig, Juan Carlos Vera, Rolf Freter, W. Jeffrey Baker, Jeffrey Y.C. Wong, Andrew A. Renshaw, Philip W. Kantoff
Publikováno v:
Journal of Clinical Oncology. 39:5011-5011
5011 Background: For men with unfavorable-risk non-metastatic (M0) prostate cancer (PC) the addition of docetaxel to radical prostatectomy (RP) or radiation therapy (RT) and androgen deprivation therapy (ADT) has been studied in 6 randomized controll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfbd834cb21459cb3d595b6bea5415b0
https://doi.org/10.1200/jco.2021.39.15_suppl.5011
https://doi.org/10.1200/jco.2021.39.15_suppl.5011